Adoptive Transfer of Haploidentical NK Cells and N-803

HIV Infections Clinical Trial

Official title:

Adoptive Transfer of Haploidentical Natural Killer Cells and IL-15 Super Agonist ALT-803 in Human Immunodeficiency Virus (HIV)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03899480
• Other study ID #: IDIM-2018-26587
• Status: Completed
• Phase: Phase 1
• Start date: May 1, 2019
• Est. completion date: April 1, 2021

Study information

• Verified date: April 2021
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot therapeutic study of related donor HLA-haploidentical NK-cell based therapy to determine if the treatment is safe and well-tolerated and if there is any measureable impact on virus reservoirs.

Description:

Human immunodeficiency virus (HIV) infection causes profound and often irreversible changes to the adaptive and innate immune system. In the absence of antiretroviral therapy (ART), Cluster of Differentiation (CD)4+ T cells are progressively depleted, CD8+ T cells are often expanded, and much of the immune system is chronically activated. Much of these abnormalities improve during long-term ART, but the system rarely returns to normal. Notably, chronic inflammation persists indefinitely during ART, and is driven by multiple factors, including HIV production (and perhaps replication), irreversible loss of the mucosal integrity and exposure to gut microbes, and an excess burden of other pathogens such as cytomegalovirus (CMV). How the virus and its host interact during effective ART is the focus of intense investigation. HIV-1 preferentially infects activated memory CD4+ T cells that express the chemokine receptor CCR5, although resting CD4+ T cells, naïve CD4+ T cells and macrophages can also be infected. The majority of infected and activated CD4+ T cells die quickly, but a small fraction reverts to a resting state and persistent indefinitely as the latent reservoir. Because ART blocks all or nearly all new infection events, the reservoir that exists at the time ART is initiated becomes the reservoir that persists for the life of the individual. This memory T cell viral reservoir is maintained during ART by the long half-life of the infected cell, homeostatic proliferation of these cells and perhaps by low levels of persistent viral replication. The viral reservoir in peripheral blood exists predominantly in those longer-lived memory CD4+ cells endowed with regenerative potential, including memory stem cells, central memory cells and transitional memory. The reservoir also persists in potentially shorter-lived CD4+ T effector cell populations, but whether these cells represent a stable reservoir or one that is constantly being regenerated via proliferation and differentiation is unknown. "Shock and Kill". One approach to curing HIV infection that has generated broad support in the field is to induce latently infected cells to produce virus (the "shock") while enhancing the ability of the host to clear these virus-producing cells (the "kill"). Histone deacetylase (HDAC) inhibitors have been shown to increase production of HIV-1 RNA and to a lesser degree virus particles from the viral reservoir in vivo. The magnitude of the effect of HDAC inhibitors is modest at best, and as of yet this class of drugs has had no consistent effect on the frequency of cells that harbor replication-competent HIV. Other classes of anti-latency drugs and immunomodulators are therefore being explored for their capacity to stimulate the viral reservoir. To augment the capacity of the host to eliminate reservoir cells following activation, several immunologic strategies are being explored. These strategies include therapeutic vaccines, monoclonal antibodies, and immune checkpoint inhibitors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: April 1, 2021
• Est. primary completion date: April 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age-18-65
• Stable ART for at least 12 months.
• Screening plasma HIV RNA levels below level of quantification (<40 to <50 copies RNA/mL depending on the assay).
• Screening CD4 count =500 cells/µl
• Laboratory tests (Complete Blood Count, Comprehensive Metabolic Panel, Mg, Phosphorus, international normalized ratio/partial thromboplastin time (INR/PTT), Thyroid stimulating hormone (TSH)/T4,) performed within 14 days of infusion of donor NK cells. All laboratory results (unless otherwise specified) must be Grade 1 or normal based on the DAIDS Adverse Event Grading Scale (Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events v2.0)
• Adequate kidney function defined by estimated Glomerular Filtration Rate (CrCl) > 60 ml/min or ml/min/1.73 m2 (= grade 2 per DAIDS) and creatinine = 1.5 x ULN
• Pulmonary Function Testing (PFT) must show FEV1 and DLCOcorr > 50% of predicted if subjects have symptomatic or prior known impairment.
• Normal transthoracic echocardiogram
• Ability to be off prednisone and other immunosuppressive drugs for at least 14 days before infusion of cells
• Women of child bearing potential and men with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy
• Voluntary written consent provided by the subject

Exclusion Criteria:

• Any condition that precludes leukapheresis, lymph node biopsy or colonoscopy with biopsy
• Active infection other than HIV currently requiring systemic antimicrobial therapy
• History of deep vein thrombosis
• Active significant, tissue invasive fungal infection requiring systemic antifungal therapy (dermatologic conditions requiring only topical therapy are allowed).
• Chronic active hepatitis B or C (defined as antibody positive and DNA+ or HepBsAG+).
• Breastfeeding
• Intended modification of antiretroviral therapy in the next 24 weeks
• NYHA (New York Heart Association) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction
• Symptomatic congestive heart failure, unstable angina pectoris, or Myocardial infarction within 6 months prior to screening
• Marked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval greater than 500 milliseconds)
• On-going chronic systemic corticosteroid use or other immunosuppressive therapy (a history of mild asthma not requiring therapy is eligible and inhaled corticosteroids is allowed. Topical steroids are allowed.)
• Psychiatric illness/social situations that would limit compliance with study requirements
• Previous diagnosis of an autoimmune disease (e.g. rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, vasculitis)
• Use of any anticoagulants within the previous 4 weeks.
• Other illness that in the opinion of the investigator would exclude the patient from participating in this study

Related Conditions & MeSH terms

• Hiv
• HIV Infections
• Immune Deficiency
• Immunologic Deficiency Syndromes

Intervention

Biological:
• Haploidentical Natural Killer (NK) Cells
infusion with N-803 activated NK cells

Locations

Country	Name	City	State
United States	University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events	Toxicity and adverse events will be classified according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events v2.0. Scale ranges from grade 0 to 4 with a grade of 0 indicating normal signs and symptoms and a grade of 4 indicating potentially life-threatening signs and symptoms. Grade 2, 3, and 4 adverse events will be considered when determining the safety and tolerability of treatment.	throughout trial participation: 100 days post infusion
Primary	CBC; White Blood Cell Count	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. White blood cell count will be evaluated by principle investigator. WBC outside of established clinical reference range (4.5-11.0 k/ul) may indicate adverse treatment reaction. Total occurrence of abnormal CBC results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CBC; Red Blood Cell Count	Complete blood count will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Red blood cell count will be evaluated by principle investigator. RBC outside established clinical reference range (2.5-5.5 mil/ul) may indicate adverse treatment reaction. Total occurrence of abnormal CBC results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 day post infusion
Primary	CBC; Hemoglobin	Complete blood count will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Hemoglobin will be evaluated by principle investigator. Hemoglobin outside established clinical reference range (14-17 g/dl) may indicate adverse treatment reaction. Total occurrence of abnormal hemoglobin results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CBC; Hematocrit	Complete blood count will be performed at days 2, 3, 10, 21 post infusion. Hematocrit will be evaluated by principle investigator. Hematocrit outside established clinical reference range (42-52%) may indicate adverse treatment reaction. Total occurrence of abnormal hematocrit results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CBC; Mean Corpuscular Volume	Complete blood count will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. MCV will be evaluated by principle investigator. MCV outside established clinical reference range (84-96 fl.) may indicate adverse treatment reaction. Total occurrence of abnormal MCV results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CBC; Mean Corpuscular Hemoglobin	Complete blood count will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. MCH will be evaluated by principle investigator. MCH outside established clinical reference range (28-34 pg) may indicate adverse treatment reaction. Total occurrence of abnormal MCH results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CBC; Mean Corpuscular Hemoglobin Concentration	Complete blood count will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. MCHC will be evaluated by principle investigator. MCHC outside established clinical reference range (33-36 g/dl) may indicate adverse treatment reaction. Total occurrence of abnormal MCHC results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Sodium	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Sodium concentration will be evaluated by principle investigator. Sodium concentration outside established clinical reference range (136-145 mmol/l) may indicate adverse treatment reaction. Total occurrence of abnormal sodium concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Potassium	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Potassium concentration will be evaluated by principle investigator. Potassium concentration outside established clinical reference range (3.5-5.1 mmol/l) may indicate adverse treatment reaction. Total occurrence of abnormal potassium concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Chloride	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Chloride concentration will be evaluated by principle investigator. Chloride concentration outside established clinical reference range (98-107 mmol/l) may indicate adverse treatment reaction. Total occurrence of abnormal chloride concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Glucose	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Glucose concentration will be evaluated by principle investigator. Glucose concentration outside established clinical reference range (70-99 mg/dl) may indicate adverse treatment reaction. Total occurrence of abnormal glucose concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Calcium	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Calcium concentration will be evaluated by principle investigator. Calcium concentration outside established clinical reference range (8.2-10.2 mg/dl) may indicate adverse treatment reaction. Total occurrence of abnormal calcium concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Blood Urea Nitrogen	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. BUN concentration will be evaluated by principle investigator. BUN concentration outside established clinical reference range (6-25 mg/dl) may indicate adverse treatment reaction. Total occurrence of abnormal BUN concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Creatinine	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Creatinine concentration will be evaluated by principle investigator. Creatinine concentration outside established clinical reference range (0.8-1.3 mg/dl) may indicate adverse treatment reaction. Total occurrence of abnormal creatinine concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Alkaline Phosphatase	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Alkaline phosphatase concentration will be evaluated by principle investigator. Alkaline phosphatase concentration outside established clinical reference range (26-137 u/l) may indicate adverse treatment reaction. Total occurrence of abnormal alkaline phosphatase concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Alanine Transaminase	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Alanine transaminase concentration will be evaluated by principle investigator. Alanine transaminase concentration outside established clinical reference range (15-65 u/l) may indicate adverse treatment reaction. Total occurrence of abnormal alanine transaminase concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Aspartate Transaminase	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Aspartate transaminase concentration will be evaluated by principle investigator. Aspartate transaminase concentration outside established clinical reference range (0-37 u/l) may indicate adverse treatment reaction. Total occurrence of abnormal aspartate transaminase concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Total Bilirubin	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Total bilirubin concentration will be evaluated by principle investigator. Total bilirubin concentration outside established clinical reference range (<1.1 mg/dl) may indicate adverse treatment reaction. Total occurrence of abnormal total bilirubin concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Albumin	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Serum albumin will be evaluated by principle investigator. Serum albumin concentration outside established clinical reference range (3.2-4.7 g/dl) may indicate adverse treatment reaction. Total occurrence of abnormal serum albumin concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Primary	CMP; Total Protein	Comprehensive metabolic panel will be performed at days 2, 3, 10, 21 post infusion to aid in the continuous assessment of safety and tolerability throughout the study. Total protein will be evaluated by principle investigator. Total protein concentration outside established clinical reference range (6.4-8.2 g/dl) may indicate adverse treatment reaction. Total occurrence of abnormal total protein concentration results will be used to determine treatment safety and tolerability.	2, 3, 10, and 21 days post infusion
Secondary	Decrease in HIV reservoirs	The secondary outcomes in this study are quantities of virus in well-defined anatomical locations (gut and lymph node). These quantities will be determined before and after administration of the NK cells and N-803 therapy based on RNAscope and DNAscope, which are technologies that measure concentration of target RNA and DNA.	100 days post infusion